What Yangzijiang Pharmaceutical does

Beijing Haiyan Pharmaceutical Co., Ltd. (扬子江药业集团北京海燕药业有限公司) is a wholly-owned subsidiary of Yangzijiang Pharmaceutical Group, established in February 2004 and headquartered on a ~99 mu (~65,979 sqm) campus in Beijing's Zhongguancun Life Science Park (Changping District). The company operates as Yangzijiang Group's only integrated R&D, manufacturing, and market expansion hub in northern China, executing a dual TCM-chemical drug ("双药并举") strategy spanning respiratory, cardiovascular, central nervous system, endocrine, and anti-infective therapeutic areas. Core marketed products include Suhuang Zhike Capsule (Suhuang Cough Capsule, the only TCM recommended in Western Medicine Cough Guidelines, entered the 2020 Chinese Pharmacopoeia), Kesu Irbesartan Tablets (antihypertensive, passed consistency evaluation), Benoic Rizatriptan Tablets (acute migraine), and Monika Racecadotril Tablets (pediatric acute diarrhea), supported by a Drug Research Institute developing additional candidates such as Xinsu ultrasound contrast agent and fat emulsion injection technology.

The subsidiary's manufacturing backbone rests on advanced pharmaceutical technology platforms, including the group's Longfentan (龙凤堂) Smart Factory for full-process digital-intelligent TCM manufacturing (automatic feeding, robot dispensing, MES systems), proprietary volatile/non-volatile fingerprint analysis methods for Suhuang (a domestic first in multi-component TCM quality control), and Box-Behnken response surface optimization for fat emulsion physical stability. Production is supported vertically through 33 standardized TCM planting bases covering 100,000 mu across China, with a dedicated Gansu base of 15,000+ mu established since 2014 and a new Longfentan industrial base launched in Gansu in 2023.

Commercially, Beijing Haiyan generates revenue through prescription pharmaceutical sales distributed exclusively via Yangzijiang Group's nationwide sales network into Chinese hospitals, pharmacies, and medical institutions, with 66 group-level products now selected in China's national volume-based procurement (集中采购) as of 2025. Pricing is governed by national reimbursement (NRDL) and centralized procurement mechanisms rather than market pricing. The group is also expanding into the "大健康" (large health) consumer segment via Huangqi Sports Drinks, Huangqi Coffee, Lanqin Throat Candy, and Yulan Skincare. Reported financials include 2018 subsidiary revenue of 991.598 million RMB with 158.68 million RMB net profit, cumulative 2004–2018 revenue of 7.418 billion RMB, and group-level 2025 international revenue growth of 425% YoY with large health segment growth of 239% YoY.

Name

Yangzijiang Pharmaceutical

Legal name

扬子江药业集团北京海燕药业有限公司

Website

https://bjhaiyan.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

251–500 employees

Short description

Beijing Haiyan Pharmaceutical is the northern China R&D-manufacturing subsidiary of Yangzijiang Pharmaceutical Group, developing and producing TCM and chemical drugs (notably Suhuang Cough Capsules, Kesu Irbesartan) for distribution through the group's national hospital sales network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Respiratory & Allergy Pharmaceuticals (HLAIAAAH)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Pharmaceutical manufacturing
• Traditional Chinese medicine
• Generic drug production
• Respiratory therapeutics
• Cardiovascular medications

Headquarters

HQ city

Changping

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing and Sales: Beijing Haiyan manufactures and sells prescription pharmaceutical products including Suhuang Cough Capsules (呼吸系统), Kesu Irbesartan Tablets (心血管), Xiaoxuan Kaduoqu Tablets (儿科), and Benoic Lizatriptan Tablets (神经系统). Products are distributed through Yangzijiang Group's nationwide sales network. Revenue primarily comes from product sales to hospitals, pharmacies, and medical institutions across China.
2. Health Consumer Products (Large Health / 大健康): Yangzijiang Group is expanding into health consumer products including Huangqi Sports Drinks, Huangqi Coffee, Lanqin Throat Candies, and Youlan Skincare products, targeting the consumer health and wellness market segment.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Beijing Haiyan Pharmaceutical is the northern China R&D-manufacturing-sales subsidiary of Yangzijiang Pharmaceutical Group, producing prescription pharmaceuticals across respiratory, cardiovascular, central nervous system, endocrine, and anti-infective therapeutic areas. The company combines traditional Chinese medicine (TCM) and chemical drug production, with flagship product Suhuang Zhike Capsule (TCM cough/asthma treatment) and core chemical drugs including Irbesartan Tablets, Rizatriptan Benzoate Tablets, and Racecadotril Tablets. Products are distributed through the parent group's nationwide sales network to hospitals, pharmacies, and medical institutions across China.

Product overview

Yangzijiang Pharmaceutical Group is a comprehensive pharmaceutical company with Beijing Haiyan Pharmaceutical as its northern R&D and production subsidiary. The company operates a dual strategy of traditional Chinese medicine and chemical drugs (中药、化药"双药并举"), with respiratory and cardiovascular systems as key therapeutic areas. Core products include Suhuang Zhike Capsule (entered 2020 Chinese Pharmacopoeia), Ke Su (Irbesartan Tablets), Hao Su (Rizatriptan), and Monika (Racecadotril). The company also develops health products under brands including Longfengtang, Lanqin, and Yulan, encompassing functional beverages like Huangqi Sports Drink, throat care products, and skincare. The portfolio spans from patented TCM formulas to generic chemical drugs, supported by drug research institutes conducting research across antiviral, nervous system, cardiovascular, endocrine, and respiratory areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Suhuang Zhike Capsule (苏黄止咳胶囊) Traditional Chinese medicine capsule for treating post-cold cough and cough variant asthma, formulated with ephedra, perilla leaf and eight other herbal ingredients. It is the only recommended TCM for cough in Western medicine guidelines with clinical total effective rate over 87%.
• Irbesartan Tablets (厄贝沙坦片) - Kesu (科苏) Antihypertensive generic medication for treating primary hypertension and diabetic nephropathy with hypertension comorbidity. Passed national consistency evaluation ensuring bioequivalence with originator brand.
• Rizatriptan Benzoate Tablets (苯甲酸利扎曲普坦片) - Haosu (豪苏) Acute migraine treatment medication for adults and children aged 6-17 years, providing relief for migraine attacks with or without aura.
• Racecadotril Tablets (消旋卡多曲片) - Monika (莫尼卡) Pediatric acute diarrhea medication providing rapid symptom relief through intestinal absorption regulation.
• Oseltamivir Phosphate Granules (磷酸奥司他韦颗粒) Antiviral medication for influenza treatment and prevention, expanded production capacity at Beijing Haiyan.
• Celecoxib Capsules (塞来昔布胶囊) NSAID medication for treating osteoarthritis, rheumatoid arthritis, and acute pain, expanded production capacity at Beijing Haiyan.
• Xinsu Contrast Agent - Perfluoropropane Human Albumin Microspheres for Injection (信苏 - 注射用全氟丙烷人血白蛋白微球) Cardiovascular diagnostic imaging agent for enhancing cardiac ultrasound imaging, a domestic ultrasound contrast agent.
• Yiqi Tongqiao Wan (益气通窍丸) Category 1.1 traditional Chinese medicine innovative drug launched nationally, representing advancement in TCM innovation drug portfolio.
• Hydrochloride Aripiprazole Tablets (盐酸阿诺达非片) Category 1 chemical innovative drug approved for marketing, expanding the innovative drug portfolio.
• Huangqi Sports Drink (黄芪运动饮) Sports nutrition beverage using pharmaceutical-food homology concept with organic Huangqi (Astragalus), designed for energy supplementation and physical recovery during exercise.
• Longfengtang Huangqi Essence (龙凤堂黄芪精) Traditional Chinese medicine health product series based on Huangqi (Astragalus), flagship health brand extending from core pharmaceutical products.
• Lanqin Throat Candy/Oral Solution (蓝芩喉糖/小蓝芩口服液) Throat care products derived from traditional Chinese medicine formulations, entering the consumer health market through convenience stores and daily consumption channels.
• Huangqi Coffee (黄芪咖啡) Coffee product infused with Huangqi (Astragalus) extracts, combining traditional Chinese medicine ingredients with modern beverage trends, exhibited at French agricultural expo.
• Yulan Skincare Products (佑兰护肤品) Plant-based skincare brand utilizing traditional Chinese medicine skin physiology and modern manufacturing technology.

Quantifiable outcome

• Suhuang Cough Capsule clinical total effective rate: 87%+
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered minor.

• 北京大学医学部药学院 (Peking University Health Science Center School of Pharmacy)minorStrategic or Co-development Partner · 23 October 2021Yangzijiang Group and Beijing Haiyan co-organized a joint sports meeting with Peking University Health Science Center School of Pharmacy on October 23, 2021. The '青春闪药·扬帆起航' event included competitive sports, team building activities, and academic exchanges. The partnership aims to build relationships with pharmacy students for future talent recruitment and strengthen industry-academia ties. Joint recruitment presentations at Shenyang Pharmaceutical University are also conducted annually.
• 北京金隅红树林环保有限公司 (Beijing BBMG Redwoods Environmental Protection Co., Ltd.)minorOthersHazardous waste disposal partner. All hazardous waste (including waste packaging materials containing chemical reagents or drugs, substandard medicines, expired drugs, waste liquids, waste chemical reagents, activated carbon, and sludge) generated by Beijing Haiyan is disposed of through this licensed hazardous waste management company, ensuring compliance with environmental regulations.
• 中环联新（北京）环境保护有限公司 (China-EMA Joint New (Beijing) Environmental Protection Co., Ltd.)minorImplementation/ SI/ Consulting PartnerEnvironmental impact assessment (EIA) agency engaged for construction projects. Conducted environmental impact assessments for new production capacity expansion (磷酸奥司他韦颗粒 and 塞来昔布胶囊) and R&D laboratory renovation projects.

Scale indicators11 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Zhejiang Huahai Pharmaceutical: Major Chinese generic and specialty pharmaceutical manufacturer with strong cardiovascular and CNS franchises, deep international presence, and significant consistency evaluation/VBP participation. Comparable in cardiovascular/CNS generics and international expansion, though broader in therapeutic coverage.
• Jiangsu Hengrui Medicine: China's largest specialty/innovative pharmaceutical company with broad therapeutic coverage and strong R&D pipeline. Comparable as a higher-scale specialty pharma peer, but significantly larger and focused on innovative chemical drugs rather than TCM.
• Shanghai Pharmaceuticals Holding: One of China's largest integrated pharmaceutical groups combining manufacturing, distribution, and retail pharmacy operations. Comparable in TCM + chemical drug manufacturing with national distribution, but operating at materially larger scale.

Direct peers

• Yunnan Baiyao Group: Major Chinese TCM manufacturer that has successfully expanded into consumer health products (toothpaste, healthcare products) leveraging its TCM heritage. Highly comparable to Beijing Haiyan's TCM + large-health dual strategy.
• Livzon Pharmaceutical Group: Integrated Chinese pharmaceutical company producing both TCM preparations and chemical drug generics across digestive, cardiovascular, and oncology areas. Comparable TCM + chemical drug dual-engine business model with similar scale and therapeutic breadth.
• Guangzhou Pharmaceutical Holdings (GPHL): Large Chinese pharma group combining TCM heritage brands (e.g. Wang Lao Ji, Banlangen) with chemical drug manufacturing and national distribution. Comparable dual TCM/chemical drug model with respiratory/cold consumer products.
• China Traditional Chinese Medicine Holdings: Hong Kong-listed TCM platform consolidating multiple TCM manufacturers across respiratory, oncology-support, and chronic disease areas. Comparable as a multi-product TCM specialty pharma operator with national distribution.
• Beijing Tongrentang Group: Historic Beijing-based TCM specialist with respiratory and chronic disease franchises and a nationwide hospital/pharmacy distribution network. Directly comparable in TCM specialty pharma positioning and respiratory therapeutic area focus.
• Salubris Pharmaceuticals: Chinese specialty pharmaceutical manufacturer focused on cardiovascular and chronic disease generics with strong consistency evaluation and centralized procurement participation. Comparable to Beijing Haiyan's cardiovascular franchise (Kesu/Irbesartan) and VBP exposure.
• China Resources Sanjiu Medical & Pharmaceutical: Leading Chinese TCM and OTC drug manufacturer with a respiratory/cold portfolio (e.g. 999 Ganmao Ling) and an expanding consumer health business. Closely comparable to Beijing Haiyan's TCM-led respiratory franchise plus consumer health extension.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance20 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yangzijiang Pharmaceutical